{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:14:31Z","timestamp":1778184871334,"version":"3.51.4"},"reference-count":88,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Gastric and gastroesophageal junction cancers remain a major global cause of cancer-related mortality. Despite incremental advances in surgery and systemic therapy, durable survival gains have been limited, underscoring persistent unmet medical needs. However, the treatment paradigm has undergone a rapid transformation, driven by the integration of immunotherapy in curative-intent systemic treatment and the expansion of biomarker-guided systemic therapies. In the perioperative setting, immune checkpoint inhibitors combined with optimized cytotoxic chemotherapy have demonstrated encouraging efficacy, with recent phase III trials contributing to the establishment of combination of immunotherapy and chemotherapy as an emerging therapeutic platform. In advanced disease, precision oncology frameworks continue to expand beyond traditional biomarkers. Established targets such as human epidermal growth factor receptor 2 are now complemented by newly validated markers including claudin18.2, whereas additional actionable alterations\u2014such as MET and TROP2\u2014are actively under clinical investigation. These developments are redefining treatment algorithms and introducing new sequencing considerations, particularly in the context of tumor heterogeneity and biomarker coexpression. Concurrent advances in molecular diagnostics and next-generation sequencing are also facilitating the comprehensive identification of therapeutically relevant alterations. This review outlines the evolving therapeutic landscape of gastric and gastroesophageal junction cancers, spanning perioperative immunotherapy, newly validated molecular targets, and next-generation drug development platforms. By integrating biomarker-driven strategies with innovative modalities, such as antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor-T-cell therapy, and vaccines, we highlight how precision therapeutics are reshaping treatment paradigms across resectable and advanced disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-518912","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:59:15Z","timestamp":1778183955000},"source":"Crossref","is-referenced-by-count":0,"title":["Promising New Platforms and Targets in the Management of Gastroesophageal Cancers"],"prefix":"10.1200","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-2392","authenticated-orcid":false,"given":"Jeesun","family":"Yoon","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Watson","sequence":"additional","affiliation":[{"name":"Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Smyth","sequence":"additional","affiliation":[{"name":"Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.096"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00156-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104000"},{"key":"e_1_3_2_8_2","article-title":"Claudin-18.2 expression in gastro-oesophageal adenocarcinoma in a Western population: Overlap with other biomarkers and prognostic value","volume":"43","author":"Herpe FV","year":"2025","unstructured":"Herpe FV, Deman F, Wit MD, et al: Claudin-18.2 expression in gastro-oesophageal adenocarcinoma in a Western population: Overlap with other biomarkers and prognostic value. J Clin Oncol 43, 2025 (suppl 16; abstr 4021)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02463"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00748"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4206","article-title":"STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma","volume":"41","author":"Klempner SJ","year":"2023","unstructured":"Klempner SJ, Shitara K, Sison A, et al: STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. J Clin Oncol 41, 2023 (suppl 16; abstr TPS4206)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01331-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2025.25.e11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072252"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70473-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02914"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00676-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00486"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103421"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102190"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01606-w"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1520"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00795"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.282"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2738"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.364"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00718-X"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0522"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03979-y"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.016"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.247"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4045"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","unstructured":"Jung J Kim ST Ko J et al: Clinical implication of HER2 aberration in patients with metastatic cancer using next-generation sequencing: A pan-tumor analysis. JCO Precis Oncol 10.1200\/PO.22.00537","DOI":"10.1200\/PO.22.00537"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6136"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03077"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02132-2"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01298-6"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61957-9"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01560-z"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00575"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0204"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS473"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00636-3"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03125-y"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2755"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01030-X"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106053"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071120"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01075-y"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01235-z"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01466-w"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4164"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4165"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0585-x"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30566-1"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5580"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1505"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.363"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf320"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT038"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1537"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4182"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-6061"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0742"},{"key":"e_1_3_2_89_2","first-page":"635","article-title":"635 A randomised, placebo-controlled, phase I\/IIa study evaluating the safety and clinical activity of a novel cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study)","volume":"12","author":"Grant M","year":"2024","unstructured":"Grant M, Kwok J, Smith P, et al: 635 A randomised, placebo-controlled, phase I\/IIa study evaluating the safety and clinical activity of a novel cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study). J Immunother Cancer 12:635, 2024","journal-title":"J Immunother Cancer"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-518912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:59:17Z","timestamp":1778183957000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-518912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-518912"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-518912","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e518912"}}